Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.06. | Hypha Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
10.06. | Hypha Labs, Inc.: Hypha Labs Files New Patent Application for Its Suite of Artificial Intelligence Techniques for Its Mushroom Accelerator | 346 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / June 10, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an Artificial Intelligence (AI) powered pioneer in functional mushroom sciences and the creator of the MicroPearls suite... ► Artikel lesen | |
HYPHA LABS Aktie jetzt für 0€ handeln | |||||
15.05. | Hypha Labs, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 2 | SEC Filings | ||
13.05. | Hypha Labs, Inc.: Hypha Labs Files Multiple Additional Patents for its Ground Breaking Mushroom Accelerator | 274 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / May 13, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls suite of products, is pleased to announce... ► Artikel lesen | |
12.05. | Hypha Labs Inc. and Emerging Markets Consulting LLC: Emerging Markets Report: A Milestone for Mycelium | 1 | GlobeNewswire (USA) | ||
01.05. | Hypha Labs, Inc.: Hypha Labs Acquires State-of-the-Art HPLC Analytic Machine and Partners with Lucidity Systems for Advanced Autosampler Upgrade | 349 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / May 1, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls suite of products, is pleased to announce... ► Artikel lesen | |
22.04. | Hypha Labs and the technology behind micropearls | 2 | The Market Herald Canada | ||
09.04. | Hypha Labs, Inc.: New Mexico Governor Signs Bill Allowing for Psilocybin Use | 254 | ACCESS Newswire | 'Medical Psilocybin Act' Provides Legal Access to Citizens for the First Time LAS VEGAS, NV / ACCESS Newswire / April 9, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences... ► Artikel lesen | |
17.03. | Hypha Labs, Inc.: Hypha Laboratories Retains Stockhouse for International Awareness Campaign | 242 | ACCESS Newswire | Venerable, Popular Destination to Introduce Hypha Labs to Canadian and U.S. Investors LAS VEGAS, NV / ACCESS Newswire / March 17, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom... ► Artikel lesen | |
14.02. | Hypha Labs, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
12.02. | Hypha Labs Inc. and Emerging Markets Consulting LLC: Emerging Markets Report: Breakthroughs & Bureaucracy | 1 | GlobeNewswire (USA) | ||
30.01. | Hypha Labs, Inc.: Hypha Laboratories Reports Significant Breakthrough for MicroPearls Yields | 283 | ACCESS Newswire | In-Home Consumer Harvests Increase Exponentially After Research Discovery at Hypha Laboratories LAS VEGAS, NEVADA / ACCESS Newswire / January 30, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional... ► Artikel lesen | |
27.01. | Hypha Labs, Inc.: Hypha Laboratories Applauds Call for Regulatory Changes for Functional Mushrooms | 260 | ACCESS Newswire | Legislative Changes Usher Acceptance, Broaden Market Opportunity for Early Adopters LAS VEGAS, NV / ACCESS Newswire / January 27, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom... ► Artikel lesen | |
24.01. | Hypha Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
16.01. | Hypha Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
13.01. | Hypha Labs, Inc. - 10-K, Annual Report | - | SEC Filings | ||
31.12.24 | Hypha Labs, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
18.11.24 | Hypha Labs, Inc.: Hypha Laboratories Announces Completion of Phase 1 of Its State-of-the-Art Facility and Arrival of V5 Working MicroPearls Prototypes | 298 | ACCESS Newswire | Advancements Enhance Efficacy in Hypha's Revolutionary Home and Commercial Production UnitsLAS VEGAS, NV / ACCESSWIRE / November 18, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom... ► Artikel lesen | |
15.10.24 | Hypha Labs, Inc.: Hypha Laboratories Establishes Scientific and Cultural Advisory Board, Adds William Padilla-Brown | 303 | ACCESS Newswire | Board Will Add to Company's Intellectual Capital and Diversity of ExperienceLAS VEGAS, NV / ACCESSWIRE / October 15, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and... ► Artikel lesen | |
07.10.24 | Hypha Labs, Inc.: Hypha Laboratories Reveals New Patent Applications for Novel A.I. Driven In-Home Mycelium Production | 301 | ACCESS Newswire | Company Intends to Bring First Functional Mushroom Producer to RetailLAS VEGAS, NV / ACCESSWIRE / October 7, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VOR BIOPHARMA | 0,890 | 0,00 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 40,330 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
VERVE THERAPEUTICS | 11,255 | 0,00 % | BMO Capital stuft Verve Therapeutics nach Eli Lilly-Übernahme herab | ||
RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
ADMA BIOLOGICS | 18,380 | 0,00 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
KYMERA THERAPEUTICS | 45,720 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
QIAGEN | 41,100 | -0,32 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
ITEOS THERAPEUTICS | 10,020 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down Operations | - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 9,550 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
KEROS THERAPEUTICS | 13,510 | 0,00 % | Keros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to Stockholders | LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 13,050 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 21,310 | 0,00 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target | ||
IMMUNOME | 8,790 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
ARS PHARMACEUTICALS | 18,090 | 0,00 % | ARS Pharmaceuticals, Inc. - 8-K, Current Report |